ASH 2014

✓

Kunin ang pagmamay-ari

I-embed ang search bar na ito sa iyong website

I-SEARCH ANG MGA NAKARAANG EPISODE

I-search ang mga nakaraang episode ng ASH 2014.

MGA NAKARAANG EPISODE 🔗

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy

Feb. 18, 2015

Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma. “By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remis…

00:04:14

Children with aggressive leukaemia experiencing remission with T cell therapy

Feb. 18, 2015

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.

00:04:37

Relapsed multiple myeloma responds to combination therapy with daratumumab

Feb. 18, 2015

Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.

00:01:49

ASH 2014: Expert discussion on the latest in AML

Feb. 18, 2015

Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv. They debate the use of intensifie…

00:09:09

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Feb. 18, 2015

Dr Craig Moskowitz of the Memorial Sloan Kettering Cancer Center, New York, USA talks to ecancertv at ASH 2014 about the findings of a phase III trial which compared brentuximab vedotin (BV), an antibody targeting the CD30 protein on Hodgkin lymphoma cells, with placebo in 327 patients at risk of p…

00:06:17

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Feb. 18, 2015

Dr Thomas Martin, MD, of the University of California, San Francisco, USA talks to ecancertv at ASH 2014 about his work looking at the use of SAR, an anti-CD38 antibody, in the treatment of aggressive multiple myeloma.

00:04:22

HIV-associated lymphoma responds well to stem cell transplantation

Feb. 18, 2015

Dr Joe Alvarnas of the City of Hope National Medical Center, Los Angeles, USA talks to ecancertv at ASH 2014 about his work looking at stem cell transplants in HIV-associated lymphoma. "They're rather extraordinary results," he says.

00:05:49

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Feb. 18, 2015

Prof Amrita Krishnan of the City of Hope National Medical Center, Los Angeles, USA "Ultimately, if you really want to 'win the game,' you have to cure the HIV and cure the lymphoma," Prof Krishnan tells ecancertv at ASH 2014, describing her work on modifying haematopoietic progenitor cells with gen…

00:05:34

Comment: T cell therapy for children with aggressive leukaemia

Feb. 18, 2015

Dr Catherine Bollard of the George Washington University, Washington, USA discusses key abstracts showcased at ASH 2014 with ecancertv. Here, she talks about Dr Stephan Grupp's work with T cell therapy for children with aggressive leukaemia, and his remarkable results. What's the next step for clin…

00:01:59